Top

Published in:

Open Access 01-12-2024 | Review

Guillain-barré syndrome (GBS) with antecedent chikungunya infection: a case report and literature review

Authors: Sreelakshmi V., Amrita Pattanaik, Srilatha Marate, Reeta S Mani, Aparna R. Pai, Chiranjay Mukhopadhyay

Published in: Neurological Research and Practice | Issue 1/2024

Abstract

Guillain-Barré Syndrome (GBS) is an autoimmune neuropathy. Antecedent infections have been seen to be significant triggering factors for developing GBS. Among them, arboviral infections are rapidly gaining importance as significant triggers, especially in the areas where they are endemic. Chikungunya, an arboviral infection that usually causes a self-limiting acute febrile illness can lead to GBS as one its severe complications. Herein, we describe a case of a 21-year-old female who presented with weakness in all four limbs and paresthesia. Nerve conduction study and cerebrospinal fluid (CSF) analysis showed axonal, demyelinating motor and sensory neuropathy with albuminocytological dissociation indicating Acute Motor and Sensory Axonal Neuropathy (AMSAN) variant of GBS. Serum IgM antibodies against ganglioside GM1 were detected. Anti-Chikungunya IgM antibodies were found in both serum and CSF samples. The patient was initiated with Intravenous Immunoglobulin (IVIG) therapy. In view of hypoxia, she was intubated and was on mechanical ventilation. After 2 weeks of being comatose, the patient gradually improved and was discharged with no sequelae.

A literature review on antecedent infections in GBS is presented alongside the case report to better understand the association of GBS with antecedent infections, especially the endemic arboviral infections like Chikungunya, Dengue and Zika. This will help in reinforcing the significance of having robust surveillance and public health control measures for infectious diseases.

Bragazzi, N. L., Kolahi, A. A., Nejadghaderi, S. A., Lochner, P., Brigo, F., Naldi, A., et al. (2021). Global, regional, and national burden of Guillain–Barré syndrome and its underlying causes from 1990 to 2019. J Neuroinflammation, 18(1), 264. https://doi.org/10.1186/s12974-021-02319-4.CrossRefPubMedPubMedCentral

Kuwabara, S. (2004). Guillain-Barré syndrome: Epidemiology, pathophysiology and management. Drugs, 64(6), 597–610. https://doi.org/10.2165/00003495-200464060-00003.CrossRefPubMed

Zheng, P., Tian, D. C., Xiu, Y., Wang, Y., & Shi, F. D. (2021). Incidence of Guillain-Barré syndrome (GBS) in China: A national population-based study. The Lancet Regional Health Western Pacific, 18, 100302. https://doi.org/10.1016/j.lanwpc.2021.100302.CrossRefPubMedPubMedCentral

Matsui, N., Nodera, H., Kuzume, D., Iwasa, N., Unai, Y., et al. (2018). Guillain-Barré syndrome in a local area in Japan, 2006–2015: An epidemiological and clinical study of 108 patients. European Journal of Neurology, 25(5), 718–724. https://doi.org/10.1111/ene.13569.CrossRefPubMed

Mathew, T., Srinivas, M., Nadig, R., Arumugam, R., & Sarma, G. R. (2014). Seasonal and monthly trends in the occurrence of Guillain-Barre syndrome over a 5-year period: A tertiary care hospital-based study from South India. Annals of Indian Academy of Neurology, 17(2), 239–241. https://doi.org/10.4103/0972-2327.132662.CrossRefPubMedPubMedCentral

Boucquey, D., Sindic, C. J., Lamy, M., Delmée, M., Tomasi, J. P., & Laterre, E. C. (1991). Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome. Journal of the Neurological Sciences, 104(1), 56–63. https://doi.org/10.1016/0022-510x(91)90216-t.CrossRefPubMed

Meshram, R. M., Merchant, S., Bokade, C. M., Bhongade, S., Patil, S., et al. (2016). Seasonal Variation in Childhood Guillain- Barre Syndrome in Central India. J Pediatr Neonatal Care, 5(6), 00201. https://doi.org/10.15406/jpnc.2016.05.00201.CrossRef

Pimentel, V., Luchsinger, V. W., Carvalho, G. L., Alcará, A. M., Esper, N. B., Marinowic, D., Zanirati, G., & da Costa, J. C. (2023). Guillain-Barré syndrome associated with COVID-19: A systematic review. Brain, behavior, & immunity - health, 28, 100578. https://doi.org/10.1016/j.bbih.2022.100578.

Bueso, T., Montalvan, V., Lee, J., Gomez, J., Ball, S., Shoustari, A., Julayanont, P., & Jumper, C. (2021). Guillain-Barre Syndrome and COVID-19: A case report. Clinical Neurology and Neurosurgery, 200, 106413. https://doi.org/10.1016/j.clineuro.2020.106413.CrossRefPubMed

10.

Chakraborty, U., Hati, A., & Chandra, A. (2021). Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication. Diabetes & Metabolic Syndrome, 15(6), 102326. https://doi.org/10.1016/j.dsx.2021.102326.CrossRef

11.

Jacobs, B. C., Rothbarth, P. H., van der Meché, F. G., Herbrink, P., Schmitz, P. I., de Klerk, M. A., & van Doorn, P. A. (1998). The spectrum of antecedent infections in Guillain-Barré syndrome: A case-control study. Neurology, 51(4), 1110–1115. https://doi.org/10.1212/wnl.51.4.1110.CrossRefPubMed

12.

Guillain–Barré syndrome (2023). https://www.who.int/news-room/fact-sheets/detail/guillain-barré-syndrome. Accessed 08 Aug 2023.

13.

Jasem, J., Marof, K., Nawar, A., Khalaf, Y., Aswad, S., Hamdani, F., Islam, M., & Kalil, A. (2013). Guillain-Barré syndrome as a cause of acute flaccid paralysis in Iraqi children: A result of 15 years of nation-wide study. BMC Neurology, 13, 195. https://doi.org/10.1186/1471-2377-13-195.CrossRefPubMedPubMedCentral

14.

Melone, M. A., Heming, N., Meng, P., Mompoint, D., Aboab, J., Clair, B., Salomon, J., Sharshar, T., Orlikowski, D., Chevret, S., & Annane, D. (2020). Early mechanical ventilation in patients with Guillain-Barré syndrome at high risk of respiratory failure: A randomized trial. Annals of Intensive care, 10(1), 128. https://doi.org/10.1186/s13613-020-00742-z.CrossRefPubMedPubMedCentral

15.

Netto, A. B., Taly, A. B., Kulkarni, G. B., Rao, U. G., & Rao, S. (2011). Mortality in mechanically ventilated patients of Guillain Barré Syndrome. Annals of Indian Academy of Neurology, 14(4), 262–266. https://doi.org/10.4103/0972-2327.91942.CrossRefPubMedPubMedCentral

16.

Arami, M. A., Yazdchi, M., & Khandaghi, R. (2006). Epidemiology and characteristics of Guillain-Barré syndrome in the northwest of Iran. Annals of Saudi Medicine, 26(1), 22–27. https://doi.org/10.5144/0256-4947.2006.22.CrossRefPubMedPubMedCentral

17.

Nagappa, M., Rahul, W., Sinha, S., Bindu, P. S., Mathuranath, P. S., Rao, S., et al. (2017). Guillain Barre Syndrome in the elderly: Experience from a tertiary-care hospital in India. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia, 46, 45–49. https://doi.org/10.1016/j.jocn.2017.08.048.CrossRefPubMed

18.

Doets, A. Y., Verboon, C., van den Berg, B., Harbo, T., Cornblath, & IGOS Consortium. (2018). Regional variation of Guillain-Barré syndrome. Brain: A Journal of Neurology, 141(10), 2866–2877. https://doi.org/10.1093/brain/awy232.CrossRefPubMed

19.

Chikungunya virus| CDC (2023). https://www.cdc.gov/chikungunya/index.html. Accessed 14 Jun 2023.

20.

Ojeda Rodriguez, J. A., Haftel, A., & Walker, I. I. I. (2023). Chikungunya Fever. In: StatPearls. Treasure Island (FL): StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK534224/. Accessed 14 Jun 2023.

21.

Gonçalves Júnior, J., de Oliveira Bringel, M., Rodrigues de Morais, L. (2022). Chikungunya Neurological Manifestations: A Systematic Literature Review IntechOpen. doi:https://doi.org/10.5772/intechopen.95525.CrossRef

22.

Thiruvengadam, K. V., Kalyanasundaram, V., & Rajgopal, J. (1965). Clinical and pathological studies on chikungunya fever in Madras city. The Indian Journal of Medical Research, 53(8), 729–744.PubMed

23.

Guillain-Barré Syndrome| Campylobacter| CDC (2022). https://www.cdc.gov/campylobacter/guillain-barre.html. Accessed 09 Aug 2023.

24.

Hao, Q., Saida, T., Kuroki, S., Nishimura, M., Nukina, M., Obayashi, H., & Saida, K. (1998). Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. Journal of Neuroimmunology, 81(1–2), 116–126. https://doi.org/10.1016/s0165-5728(97)00166-5.CrossRefPubMed

25.

Constant, O. C., Bentley, C. C., Denman, A. M., Lehane, J. R., & Larson, H. E. (1983). The Guillain-Barré syndrome following Campylobacter enteritis with recovery after plasmapheresis. The Journal of Infection, 6(1), 89–91. https://doi.org/10.1016/s0163-4453(83)95881-4.CrossRefPubMed

26.

Molnar, G. K., Mertsola, J., & Erkko, M. (1982). Guillain-Barré syndrome associated with campylobacter infection. British Medical Journal (Clinical Research ed), 285(6342), 652. https://doi.org/10.1136/bmj.285.6342.652.CrossRefPubMed

27.

Pryor, W. M., Freiman, J. S., Gillies, M. A., & Tuck, R. R. (1984). Guillain-Barré syndrome associated with Campylobacter infection. Australian and New Zealand Journal of Medicine, 14(5), 687–688. https://doi.org/10.1111/j.1445-5994.1984.tb05033.x.CrossRefPubMed

28.

Speed, B., Kaldor, J., & Cavanagh, P. (1984). Guillain-Barré syndrome associated with Campylobacter jejuni enteritis. The Journal of Infection, 8(1), 85–86. https://doi.org/10.1016/s0163-4453(84)93516-3.CrossRefPubMed

29.

Hao, Y., Wang, W., Jacobs, B. C., Qiao, B., Chen, M., Liu, D., Feng, X., & Wang, Y. (2019). Antecedent infections in Guillain-Barré syndrome: A single-center, prospective study. Annals of Clinical and Translational Neurology, 6(12), 2510–2517. https://doi.org/10.1002/acn3.50946.CrossRefPubMedPubMedCentral

30.

Mamishi, S., Ashrafi, M. R., Mohammadi, M., Zamani, G., Pourakbari, B., Mahmoudi, S., & Aziz-Ahari, S. (2021). Cytomegalovirus infection and Guillain-Barré syndrome: The First Case-Control Study in Iran. Iranian Journal of Child Neurology, 15(4), 35–41. https://doi.org/10.22037/ijcn.v15i4.31285.CrossRefPubMedPubMedCentral

31.

Leung, J., Sejvar, J. J., Soares, J., & Lanzieri, T. M. (2020). Guillain-Barré syndrome and antecedent cytomegalovirus infection, USA 2009–2015. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(4), 885–891. https://doi.org/10.1007/s10072-019-04156-z.CrossRefPubMed

32.

Abidoye, O., Raybon-Rojas, E., & Ogbuagu, H. (2022). A rare case of Epstein-Barr Virus: Infectious mononucleosis complicated by Guillain-Barré Syndrome. Cureus, 14(1), e21085. https://doi.org/10.7759/cureus.21085.CrossRefPubMedPubMedCentral

33.

Gupta, M., Monjazeb, S., Rosser, T., Santoro, J. D., & Ahsan, N. (2023). A case of Pediatric Guillain-Barré Syndrome after respiratory syncytial virus infection. Pediatric Neurology, 146, 129–131. https://doi.org/10.1016/j.pediatrneurol.2023.06.013.CrossRefPubMed

34.

Zheng, X., Yu, L., Xu, Q., Gu, S., & Tang, L. (2018). Guillain-Barre syndrome caused by hepatitis E infection: Case report and literature review. BMC Infectious Diseases, 18(1), 50. https://doi.org/10.1186/s12879-018-2959-2.CrossRefPubMedPubMedCentral

35.

Blecker, E., & Ehtsham, M. (2021). Guillain-Barré Syndrome Likely due to Relapsing Hepatitis A. Case reports in hepatology, 2021, 5570027. https://doi.org/10.1155/2021/5570027.

36.

Wei, J., & Duan, S. (2021). Severe Guillain-Barré syndrome associated with chronic hepatitis B: A case report and literature review. Medicine, 100(48), e27989. https://doi.org/10.1097/MD.0000000000027989.CrossRefPubMedPubMedCentral

37.

Figueiredo, C. A., Klautau, G. B., Afonso, A. M., Castrignano, S. B., Oliveira, M. I., et al. (2008). Isolation and genotype analysis of Rubella virus from a case of Guillain-Barré syndrome. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology, 43(3), 343–345. https://doi.org/10.1016/j.jcv.2008.07.015.CrossRefPubMed

38.

Cao-Lormeau, V. M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., Dub, T., et al. (2016). Guillain-Barré syndrome outbreak associated with Zika virus infection in French polynesia: A case-control study. Lancet (London England), 387(10027), 1531–1539. https://doi.org/10.1016/S0140-6736(16)00562-6.CrossRefPubMed

39.

Koike, H., Chiba, A., & Katsuno, M. (2021). Emerging infection, vaccination, and Guillain-Barré syndrome: A review. Neurology and Therapy, 10(2), 523–537. https://doi.org/10.1007/s40120-021-00261-4.CrossRefPubMedPubMedCentral

40.

Assesssment and management of Guillain-Barré syndrome in the context of Zika virus infection: interim guidance update (2016). https://www.who.int/publications-detail-redirect/WHO-ZIKV-MOC-16.4-Rev.1. Accessed 8 Jun 2023.

41.

Leonhard, S. E., Tan, C. Y., van der Eijk, A. A., Reisin, R. R., Franken, S. C., Huizinga, R., et al. (2021). Antecedent infections in Guillain-Barré syndrome in endemic areas of arbovirus transmission: A multinational case-control study. Journal of the Peripheral Nervous System: JPNS, 26(4), 449–460. https://doi.org/10.1111/jns.12469.CrossRefPubMed

42.

Arriaga-Nieto, L., Hernández-Bautista, P. F., Vallejos-Parás, A., Grajales-Muñiz, C., et al. (2022). Predict the incidence of Guillain Barré Syndrome and Arbovirus infection in Mexico, 2014–2019. PLOS Global Public Health, 2(3), e0000137. https://doi.org/10.1371/journal.pgph.0000137.CrossRefPubMedPubMedCentral

43.

Verma, R., Sharma, P., Garg, R. K., Atam, V., Singh, M. K., & Mehrotra, H. S. (2011). Neurological complications of dengue fever: Experience from a tertiary center of north India. Annals of Indian Academy of Neurology, 14(4), 272–278. https://doi.org/10.4103/0972-2327.91946.CrossRefPubMedPubMedCentral

44.

Dutta, D., Debnath, M., Nagappa, M., Das, S. K., Wahatule, R., Sinha, S., Taly, A. B., & Ravi, V. (2021). Antecedent infections in Guillain-Barré syndrome patients from south India. Journal of the Peripheral Nervous System: JPNS, 26(3), 298–306. https://doi.org/10.1111/jns.12459.CrossRefPubMed

45.

Lebrun, G., Chadda, K., Reboux, A. H., Martinet, O., & Gaüzère, B. A. (2009). Guillain-Barré syndrome after chikungunya infection. Emerging Infectious Diseases, 15(3), 495–496. https://doi.org/10.3201/eid1503.071482.CrossRefPubMedPubMedCentral

46.

Lemant, J., Boisson, V., Winer, A., Thibault, L., André, H., Tixier, F., Lemercier, M., Antok, E., Cresta, M. P., Grivard, P., et al. (2008). Serious acute Chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005–2006. Critical care Medicine, 36(9), 2536–2541. https://doi.org/10.1097/CCM.0b013e318183f2d2.CrossRefPubMed

47.

Balavoine, S., Pircher, M., Hoen, B., Herrmann-Storck, C., Najioullah, F., Madeux, B., Signate, A., Valentino, R., Lannuzel, A., Saint Louis, M., Cassadou, S., Cabié, A., & Schepers, K. (2017). Guillain-Barré Syndrome and Chikungunya: Description of all cases diagnosed during the 2014 outbreak in the French West Indies. The American Journal of Tropical Medicine and Hygiene, 97(2), 356–360. https://doi.org/10.4269/ajtmh.15-0753.CrossRefPubMedPubMedCentral

48.

Villamil-Gómez, W., Silvera, L. A., Páez-Castellanos, J., & Rodriguez-Morales, A. J. (2016). Guillain-Barré syndrome after Chikungunya infection: A case in Colombia. Enfermedades Infecciosas y Microbiologia Clinica, 34(2), 140–141. https://doi.org/10.1016/j.eimc.2015.05.012.CrossRefPubMed

49.

Matos, A. M. B., Carvalho, M., Malta, F. M., Rodrigues, D. L., Félix, C. L., Pannuti, A. C., Lima, C. S., Espósito, A. D. D. R., Santos, D. L. A. D., von Glehn, L. M. B., Colares, F., da Fonseca, J. K. B., de Oliveira, B. A. L., A. C. P., & Romano, C. M. (2020). High proportion of Guillain-Barré syndrome associated with chikungunya in Northeast Brazil. Neurology(R) Neuroimmunology & Neuroinflammation, 7(5), e833. https://doi.org/10.1212/NXI.0000000000000833.CrossRef

50.

do Rosário, M. S., de Jesus, P. A. P., Farias, D. S., Novaes, M. A. C., Francisco, M. V. L. O., Santos, C. S., Moura, D., Lima, F. W. M., Alcantara, L. C. J., & de Siqueira, I. C. (2022). Guillain-Barré Syndrome and Miller Fisher Syndrome in Association with an arboviral outbreak: A Brazilian Case Series. Frontiers in Medicine, 9, 911175. https://doi.org/10.3389/fmed.2022.911175.CrossRefPubMedPubMedCentral

51.

Agarwal, A., Vibha, D., Srivastava, A. K., Shukla, G., & Prasad, K. (2017). Guillain-Barre syndrome complicating Chikungunya virus infection. Journal of Neurovirology, 23(3), 504–507. https://doi.org/10.1007/s13365-017-0516-1.CrossRefPubMed

52.

Mahto, S. K., Gupta, P. K., Singh, A., & Meena, R. C. (2018). Atypical neurological manifestations of Chikungunya Fever: Two case reports. Indian Journal of Critical care Medicine: peer-reviewed Official Publication of Indian Society of Critical Care Medicine, 22(4), 306–308. https://doi.org/10.4103/ijccm.IJCCM_459_17.CrossRefPubMed

53.

Hameed, S., & Khan, S. (2019). Rare variant of Guillain-Barré syndrome after chikungunya viral fever. BMJ case Reports, 12(4), e228845. https://doi.org/10.1136/bcr-2018-228845.CrossRefPubMedPubMedCentral

54.

van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B. C., & van Doorn, P. A. (2014). Guillain-Barré syndrome: Pathogenesis, diagnosis, treatment and prognosis. Nature Reviews Neurology, 10(8), 469–482. https://doi.org/10.1038/nrneurol.2014.121.CrossRefPubMed

55.

Nyati, K. K., & Nyati, R. (2013). Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: An update. BioMed Research International, 2013, 852195. https://doi.org/10.1155/2013/852195.CrossRefPubMedPubMedCentral

56.

Finsterer, J. (2022). Triggers of Guillain-Barré Syndrome: Campylobacter jejuni predominates. International Journal of Molecular Sciences, 23(22), 14222. https://doi.org/10.3390/ijms232214222.CrossRefPubMedPubMedCentral

57.

Shahrizaila, N., & Yuki, N. (2011). Guillain-barré syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder. Journal of biomedicine & biotechnology, 2011, 829129. https://doi.org/10.1155/2011/829129.

58.

Saeed, M. L., Baloch, K., Mahmud, B., Khan, S. N., Qureshi, M. T., Shad, M. S. S., Hussain, Z. S., Munawar, S. W., Qadeer, K., A., & Abdullah, A. (2019). Role of anti-ganglioside antibodies in the diagnosis of Guillain-Barré Syndrome as an alternate investigation. Cureus, 11(5), e4625. https://doi.org/10.7759/cureus.4625.CrossRefPubMedPubMedCentral

59.

Goodfellow, J. A., Bowes, T., Sheikh, K., Odaka, M., Halstead, S. K., Humphreys, P. D., Wagner, E. R., Yuki, N., Furukawa, K., Furukawa, K., Plomp, J. J., & Willison, H. J. (2005). Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 25(7), 1620–1628. https://doi.org/10.1523/JNEUROSCI.4279-04.2005.CrossRefPubMed

60.

Susuki, K., Rasband, M. N., Tohyama, K., Koibuchi, K., Okamoto, S., Funakoshi, K., Hirata, K., Baba, H., & Yuki, N. (2007). Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 27(15), 3956–3967. https://doi.org/10.1523/JNEUROSCI.4401-06.2007.CrossRefPubMed

61.

Dutta, D., Debnath, M., Seshagiri, D. V., Nair, B. V. S., Das, S. K., Wahatule, R., Sinha, S., Ravi, V., Taly, A. B., & Nagappa, M. (2022). Impact of antecedent infections on the antibodies against gangliosides and Ganglioside complexes in Guillain-Barré syndrome: A correlative study. Annals of Indian Academy of Neurology, 25(3), 401–406. https://doi.org/10.4103/aian.aian_121_22.CrossRefPubMedPubMedCentral

62.

Beaver, J. T., Mills, L. K., Swieboda, D., Lelutiu, N., Esser, E. S., Antao, O. Q., Scountzou, E., Williams, D. T., Papaioannou, N., Littauer, E. Q., & Skountzou, I. (2020). Zika virus-induced neuro-ocular pathology in immunocompetent mice correlates with anti-ganglioside autoantibodies. Human Vaccines & Immunotherapeutics, 16(9), 2092–2108. https://doi.org/10.1080/21645515.2020.1775459.CrossRef

63.

Nico, D., Conde, L., Rivera-Correa, J. L., Vasconcelos-Dos-Santos, A., et al. (2018). Prevalence of IgG autoantibodies against GD3 Ganglioside in Acute Zika Virus infection. Frontiers in Medicine, 5, 25. https://doi.org/10.3389/fmed.2018.00025.CrossRefPubMedPubMedCentral

64.

Simões, J. L. B., & Bagatini, M. D. (2021). Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome. Journal of Neuroimmune Pharmacology: The Official Journal of the Society on NeuroImmune Pharmacology, 16(1), 48–58. https://doi.org/10.1007/s11481-020-09980-1.CrossRefPubMed

65.

Dufour, C., Co, T. K., & Liu, A. (2021). GM1 ganglioside antibody and COVID-19 related Guillain Barre Syndrome - a case report, systemic review and implication for vaccine development. Brain Behavior & immunity - health, 12, 100203. https://doi.org/10.1016/j.bbih.2021.100203.CrossRef

66.

Chan, M., Han, S. C., Kelly, S., Tamimi, M., Giglio, B., & Lewis, A. (2021). A Case Series of Guillain-Barré Syndrome after COVID-19 infection in New York. Neurology Clinical Practice, 11(4), e576–e578. https://doi.org/10.1212/CPJ.0000000000000880.CrossRefPubMedPubMedCentral

67.

Ziganshin, R. H., Ivanova, O. M., Lomakin, Y. A., Belogurov, A. A. Jr, Kovalchuk, S. I., Azarkin, I. V., Arapidi, G. P., Anikanov, N. A., Shender, V. O., Piradov, M. A., Suponeva, N. A., Vorobyeva, A. A., Gabibov, A. G., Ivanov, V. T., & Govorun, V. M. (2016). The pathogenesis of the demyelinating form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and immunological profiling of physiological fluids. Molecular & Cellular Proteomics: MCP, 15(7), 2366–2378. https://doi.org/10.1074/mcp.M115.056036.CrossRefPubMedCentral

68.

Ferreira da Silva, I. R., Frontera, J. A., Moreira, & Nascimento, O. J. (2016). News from the battlefront: Zika virus-associated Guillain-Barré syndrome in Brazil. Neurology, 87(15), e180–e181. https://doi.org/10.1212/WNL.0000000000003024.CrossRefPubMed

69.

Cerny, T., Schwarz, M., Schwarz, U., Lemant, J., Gérardin, P., & Keller, E. (2017). The range of neurological complications in Chikungunya Fever. Neurocritical care, 27(3), 447–457. https://doi.org/10.1007/s12028-017-0413-8.CrossRefPubMed

70.

Nyati, K. K., & Prasad, K. N. (2014). Role of cytokines and toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome. Mediators of Inflammation, 2014, 758639. https://doi.org/10.1155/2014/758639.CrossRefPubMedPubMedCentral

71.

Fokke, C., van den Berg, B., Drenthen, J., Walgaard, C., van Doorn, P. A., & Jacobs, B. C. (2014). Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain: A Journal of Neurology, 137(Pt 1), 33–43. https://doi.org/10.1093/brain/awt285.CrossRefPubMed

72.

Keesen, T. S. L., de Almeida, R. P., Gois, B. M., Peixoto, R. F., Pachá, A. S. C., Vieira, F. C. F., Paixão, M., Cazzaniga, R., Boyton, R. J., & Altmann, D. M. (2017). Guillain-Barré syndrome and arboviral infection in Brazil. The Lancet Infectious Diseases, 17(7), 693–694. https://doi.org/10.1016/S1473-3099(17)30333-X.CrossRefPubMed

73.

Ho, T. W., Hsieh, S. T., Nachamkin, I., Willison, H. J., Sheikh, K., Kiehlbauch, J., Flanigan, K., McArthur, J. C., Cornblath, D. R., McKhann, G. M., & Griffin, J. W. (1997). Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology, 48(3), 717–724. https://doi.org/10.1212/wnl.48.3.717.CrossRefPubMed

74.

Lehmann, H. C., Jangouk, P., Kierysch, E. K., Meyer zu Hörste, G., Hartung, H. P., & Kieseier, B. C. (2010). Autoantibody-mediated dysfunction of sympathetic neurons in guillain-barre syndrome. Archives of Neurology, 67(2), 203–210. https://doi.org/10.1001/archneurol.2009.331.CrossRefPubMed

75.

van Doorn, P. A., Ruts, L., & Jacobs, B. C. (2008). Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. The Lancet Neurology, 7(10), 939–950. https://doi.org/10.1016/S1474-4422(08)70215-1.CrossRefPubMed

76.

Nakamura, Y., Motoki, M., Hirose, T., Hosokawa, T., Ishida, S., & Arawaka, S. (2019). Fulminant Guillain-Barré syndrome showing severe pharyngeal-cervical-brachial weakness in the recovery phase: A case report. BMC Neurology, 19(1), 145. https://doi.org/10.1186/s12883-019-1376-5.CrossRefPubMedPubMedCentral

77.

Mustafa, A., Adio, B., & Yarahmadi, A. (2021). Descending paralysis as an atypical presentation of Guillain-Barré Syndrome. SAGE open Medical case Reports, 9, 2050313X20986662. https://doi.org/10.1177/2050313X20986662.CrossRefPubMedPubMedCentral

78.

Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., Kusunoki, S., Pardo, C. A., Reisin, R., Sejvar, J. J., Shahrizaila, N., Soares, C., Umapathi, T., Wang, Y., Yiu, E. M., Willison, H. J., & Jacobs, B. C. (2019). Diagnosis and management of Guillain-Barré syndrome in ten steps. Nature Reviews Neurology, 15(11), 671–683. https://doi.org/10.1038/s41582-019-0250-9.CrossRefPubMedPubMedCentral

79.

Singh, G., Bell, D., Rasuli, B., et al. (2021). Guillain-Barré syndrome. Reference Article Radiopaedia org. https://doi.org/10.53347/rID-7533. https://radiopaedia.org/articles/guillain-barre-syndrome-2 Accessed on 05 Oct 2023.CrossRef

80.

Head, V. A., & Wakerley, B. R. (2016). Guillain-Barré syndrome in general practice: Clinical features suggestive of early diagnosis. The British Journal of General Practice: The Journal of the Royal College of General Practitioners, 66(645), 218–219. https://doi.org/10.3399/bjgp16X684733.CrossRefPubMed

81.

Witsch, J., Galldiks, N., Bender, A., Kollmar, R., Bösel, J., Hobohm, C., Günther, A., Schirotzek, I., Fuchs, K., & Jüttler, E. (2013). Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation. Journal of Neurology, 260(5), 1367–1374. https://doi.org/10.1007/s00415-012-6806-x.CrossRefPubMed

82.

Abdelnabi, R., Kovacikova, K., Moesslacher, J., Donckers, K., Battisti, V., Leyssen, P., Langer, T., Puerstinger, G., Quérat, G., Li, C., Decroly, E., Tas, A., Marchand, A., Chaltin, P., Coutard, B., van Hemert, M., Neyts, J., & Delang, L. (2020). Novel class of Chikungunya Virus small molecule inhibitors that targets the viral Capping Machinery. Antimicrobial Agents and Chemotherapy, 64(7), e00649–e00620. https://doi.org/10.1128/AAC.00649-20.CrossRefPubMedPubMedCentral

83.

Feibelman, K. M., Fuller, B. P., Li, L., LaBarbera, D. V., & Geiss, B. J. (2018). Identification of small molecule inhibitors of the Chikungunya virus nsP1 RNA capping enzyme. Antiviral Research, 154, 124–131. https://doi.org/10.1016/j.antiviral.2018.03.013.CrossRefPubMedPubMedCentral

84.

Kovacikova, K., & van Hemert, M. J. (2020). Small-molecule inhibitors of Chikungunya Virus: Mechanisms of Action and Antiviral Drug Resistance. Antimicrobial Agents and Chemotherapy, 64(12), e01788–e01720. https://doi.org/10.1128/AAC.01788-20.CrossRefPubMedPubMedCentral

Title: Guillain-barré syndrome (GBS) with antecedent chikungunya infection: a case report and literature review
Authors: Sreelakshmi V.
Amrita Pattanaik
Srilatha Marate
Reeta S Mani
Aparna R. Pai
Chiranjay Mukhopadhyay
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Neurological Research and Practice / Issue 1/2024
Electronic ISSN: 2524-3489
DOI: https://doi.org/10.1186/s42466-024-00315-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Guillain-barré syndrome (GBS) with antecedent chikungunya infection: a case report and literature review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Brivaracetam and topiramate serum levels during pregnancy and delivery: a case report and a review of literature

Characteristics associated with occurrence of stroke in patients with infective endocarditis – a retrospective cohort study

Effects of transsectoral long-term neurorehabilitation

Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review

Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study

Reevaluating the relevance of 18F-FDG PET findings for diagnosis of neurosarcoidosis: a case series